Albany, NY -- (SBWIRE) -- 04/23/2019 -- Limb Girdle Muscular Dystrophy - Epidemiology and Market Forecast-2028

22 April 2019

LGMD prevalence ranges from 4-7 per 100,000

1. Calpainopathy is the most prevalent form in Southern Europe, while in Northern Europe calpainopathy can be unfrequent; but LGMD 2I is common.
2. A large proportion of recessive LGMD cases is due to dysferlinopathy, sarcoglycanopathies.
3. Among LGMD2, the types 2A (calpain-3), 2B (dysferlin), and 2I (fukutin-related protein) appear to be the more common subtypes with high prevalence rate. As a group, the sarcoglycanopathies (LGMDs 2C, 2D, 2E, and 2F) are nearly as frequent to be reported with carrier frequency can be estimated at 1:150.

(Albany, US) DelveInsight launched a new report on Limb-Girdle Muscular Dystrophy Market Insights, Epidemiology and Market Forecast-2028

Request for sample pages

Key benefits

1. Limb Girdle Muscular Dystrophy market report covers a descriptive overview and comprehensive insight of the LGMD epidemiology and Limb Girdle Muscular Dystrophy market in the 7 MM (United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Limb Girdle Muscular Dystrophy market report provides insights on the current and emerging therapies.
3. LGMD Dystrophy market report provides a global historical and forecasted market covering drug outreach in 7 MM.
4. Limb Girdle Muscular Dystrophy market report provides an edge that will help in developing business strategies, by understanding trends shaping and driving the Limb Girdle Muscular Dystrophy market.

"LGMD2F is a rare form of the disease that was reported for the first time from Brazil"

Limb Girdle Muscular Dystrophy disease costs around USD 15,000-17,000 per patient annually and the indirect cost is more as the condition results in loss of family income in order to provide the supportive care as well as daily care which incurred to be around USD 12,000-15,000. Currently, there is no medical treatment available that is designed specifically to target LGMD.

As there is no cure and approved therapies, current research is mostly focused on the use of novel gene therapies in order to treat the underlying genetic changes. For this, various research institutes and pharmaceutical companies are working in order to find out the ways to deliver the genes and cells to restore and repair the impaired protein function.

Several companies are using pioneering technologies such as gene therapy, RNA interference and Stem cell therapies for the delivery of corrective genes in order to provide novel treatment options. Major pharmaceutical companies, such as

1. Myonexus Therapeutics
2. Sarepta Therapeutics
3. Pfizer
4. ARMGO Pharma
and many others.

Drugs that are involved are
1. MYO-101
2. ATYR1940
And many others

Table of contents
1. Report Introduction
2. Limb-Girdle Muscular Dystrophy Market Overview at a Glance
3. LGMD Disease Background and Overview
4. Assumptions and Caveats
4.1. Limb-Girdle Muscular Dystrophy Geography Wise Prevalent Cases
4.2. United States
4.3. EU-5
4.4. Germany
4.5. Italy
4.6. Spain
4.7. France
4.8. United Kingdom
4.9. Japan
5. LGMD Treatment Practices
6. LGMD Key Emerging Therapies
7. Limb-Girdle Muscular Dystrophy Market Size
7.1. Key Findings
7.2. Total 7MM LGMD Market Analysis
7.3. Overview of Total Limb-Girdle Muscular Dystrophy Market
7.4. 7MM LGMD Country-Wise Market Analysis
7.4.1. United States
7.4.2. Germany
7.4.3. France
7.4.4. United Kingdom
7.4.5. Spain
7.4.6. Italy
7.4.7. Japan
8. Market Drivers
9. Market Barriers
10. Report Methodology
11. DelveInsight Capabilities
12. Disclaimer
13. About DelveInsight

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Contact us:
Shruti Thakur
info@delveinsight.com
+919650213330
SOURCE DelveInsight